 |
| |
| Sep-15-17 | Initiated |
RBC Capital Mkts |
Sector Perform |
$319 |
|
| Jul-26-17 | Upgrade |
Goldman |
Neutral → Buy |
|
|
| Jul-11-17 | Resumed |
Jefferies |
Hold |
|
|
| Jun-23-17 | Initiated |
Deutsche Bank |
Buy |
$315 |
|
| Jun-19-17 | Upgrade |
UBS |
Sell → Neutral |
$262 → $270 |
|
| Mar-16-17 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| Mar-16-17 | Downgrade |
Leerink Partners |
Outperform → Mkt Perform |
|
|
| Mar-02-17 | Initiated |
Instinet |
Buy |
$345 |
|
| Feb-07-17 | Upgrade |
Citigroup |
Neutral → Buy |
|
|
| Dec-29-16 | Reiterated |
Raymond James |
Strong Buy |
$375 → $386 |
|
| Dec-09-16 | Reiterated |
Stifel |
Hold |
$291 → $298 |
|
| Nov-08-16 | Initiated |
Mizuho |
Buy |
$290 |
|
| Nov-07-16 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
|
|
| Nov-07-16 | Upgrade |
Leerink Partners |
Mkt Perform → Outperform |
|
|
| Sep-06-16 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Jun-29-16 | Initiated |
Bernstein |
Outperform |
|
|
| Jun-07-16 | Downgrade |
Citigroup |
Buy → Neutral |
|
|
| Feb-25-16 | Initiated |
Citigroup |
Buy |
$345 |
|
| Jan-20-16 | Initiated |
Credit Suisse |
Neutral |
|
|
| Jan-07-16 | Initiated |
Standpoint Research |
Buy |
$360 |
|
|
|
| Sep-19-17 10:41AM | Profit From the Biogen Inc (BIIB) Stock Dip! InvestorPlace |
| 07:01AM | Apple Leads 7 Top Stocks Holding In Buy Range Investor's Business Daily |
| Sep-18-17 11:35AM | Gilead Sciences: Is The Kite Deal Too Little, Too Late? Barrons.com |
| Sep-16-17 08:03AM | Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020? Motley Fool |
| Sep-14-17 05:01PM | Biosimilar 2017 Progress Report: Stocks in Focus Zacks |
| Sep-13-17 10:05AM | 4 Biotech Stocks for the Long-Term InvestorPlace |
| Sep-12-17 08:49AM | What Is Biogen Incs (BIIB) Share Price Doing? Simply Wall St. |
| 08:06AM | See what the IHS Markit Score report has to say about Biogen Inc. Markit |
| 07:30AM | Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical Business Wire |
| Sep-11-17 10:10AM | See what the IHS Markit Score report has to say about Biogen Inc. Markit |
| 09:33AM | Why Biogen Stock Raced Higher In August Motley Fool |
| 08:36AM | Whats Gilead Sciences Valuation? Market Realist |
| Sep-08-17 10:22AM | See what the IHS Markit Score report has to say about Biogen Inc. Markit |
| Sep-07-17 05:52PM | Despite biotech's epic run, these names are still a barga... CNBC Videos |
| Sep-06-17 04:01PM | Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Business Wire |
| Sep-01-17 07:45AM | These 4 Biotechs Just Moved Into Buy Zones; Is This Giant Next? Investor's Business Daily |
| 07:00AM | Featured Company News - Ionis Earns Regulatory Milestone Payment from Biogen for SPINRAZA ACCESSWIRE |
| Aug-29-17 11:29AM | Biogen Alzheimer's Drug Shows Promise in Long-Term Study Zacks |
| 08:03AM | See what the IHS Markit Score report has to say about Biogen Inc. Markit |
| 07:38AM | Trade of the Day: Biogen Inc (BIIB) Stock Is Coiling InvestorPlace |
| 07:00AM | S&P 500 Futures Fall Sharply On North Korea Launch Investor's Business Daily |
| Aug-28-17 04:35PM | Biogen's Alzheimer's Drug Shows Promise Could It Break Out? Investor's Business Daily |
| 10:35AM | Head of Biogen's copycat drug unit leaves to join Scangos startup American City Business Journals |
| 08:02AM | See what the IHS Markit Score report has to say about Biogen Inc. Markit |
| 07:40AM | Featured Company News - IMRALDI(R), Biogen's Version of AbbVie's Humira(R), Approved in the European Union ACCESSWIRE |
| 07:30AM | Biogen Reports New Data from Phase 1b Study of Investigational Alzheimers Disease Treatment Aducanumab Business Wire |
| Aug-27-17 08:01AM | Consider This Before You Buy Biogen Motley Fool |
| Aug-25-17 11:13AM | Biogen's Humira Biosimilar Imraldi Gets Approval in EU Zacks |
| 12:00AM | Samsung, Biogen version of AbbVie's Humira approved in Europe Reuters |
| Aug-24-17 08:57PM | Samsung, Biogen version of AbbVie's Humira approved in Europe Reuters |
| 07:05PM | IMRALDI®, Biogens Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union Business Wire |
| 09:07AM | How Ioniss Spinraza Performed in 2Q17 Market Realist |
| Aug-23-17 06:06PM | Ionis Reports Revenue Growth in 2Q17 Market Realist |
| 03:42PM | Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much Motley Fool |
| 07:56AM | Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe Zacks |
| 07:37AM | How Allergans International Segment Performed in 2Q17 Market Realist |
| Aug-22-17 05:29PM | ETF Topper: Biotechnology Isn't Totally on the Outs Barrons.com |
| 09:07AM | How Allergans US Specialized Therapeutics Segment Performed in 2Q17 Market Realist |
| Aug-21-17 09:31AM | Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why Zacks |
| 12:23AM | [$$] Biogen Treads Tricky Path Between Politicians, Investors The Wall Street Journal |
| Aug-18-17 06:24PM | [$$] Biogen Treads Tricky Path Between Politicians, Investors The Wall Street Journal |
| Aug-17-17 01:16PM | What's Up With Biogen? Barrons.com |
| 08:10AM | Today's Research Reports on Stocks to Watch: Biogen Inc. and MannKind Corporation ACCESSWIRE |
| 08:02AM | See what the IHS Markit Score report has to say about Biogen Inc. Markit |
| Aug-16-17 02:30PM | Goldman Sachs Bet on Biogens Potential Landmark Alzheimers Drug Props Up Stock Fortune |
| 12:40PM | Biogen gains $1B in value after Goldman Sachs touts Alzheimers drug American City Business Journals |
| 10:51AM | Goldman has a new favorite biotech because of potential Alzheimer's blockbuster CNBC |
| 10:46AM | Goldman has a new favorite biotech because of potential A... CNBC Videos |
| 10:08AM | Biogen: Goldman Has Conviction! Barrons.com |
| 10:07AM | Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List TheStreet.com |
| 09:18AM | Goldman has a new favorite biotech because of potential Alzheimer's blockbuster CNBC |
| 09:12AM | Goldman Sachs adds Biogen to its Americas Conviction List MarketWatch |
| 08:02AM | See what the IHS Markit Score report has to say about Biogen Inc. Markit |
| Aug-15-17 07:36AM | Pfizers Declining-Revenue Products in 2Q17 Market Realist |
| Aug-12-17 08:02AM | See what the IHS Markit Score report has to say about Biogen Inc. Markit |
| Aug-11-17 04:07PM | Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs Motley Fool |
| Aug-10-17 08:04AM | IHS Markit Score downgrades Biogen Inc to 60 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit |
| 07:00AM | AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene GlobeNewswire |
| Aug-09-17 09:52AM | The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix Zacks |
| 08:04AM | See what the IHS Markit Score report has to say about Biogen Inc. Markit |
| Aug-08-17 04:33PM | Top Analyst Reports for Biogen, Activision & Cigna Zacks |
| 04:05PM | ETFs with exposure to Biogen, Inc. : August 8, 2017 Capital Cube |
| Aug-07-17 09:31AM | These 3 Biotechs Just Crushed Analyst Expectations Motley Fool |
| Aug-03-17 04:01PM | AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa GlobeNewswire |
| Aug-01-17 05:48PM | Is a Beat in Store for Ionis (IONS) This Earnings Season? Zacks |
| 12:26AM | 3 ETFs to Watch Out for on Biotech Earnings Zacks |
| Jul-31-17 09:00AM | Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences Business Wire |
| Jul-28-17 10:00AM | Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies PR Newswire |
| 09:08AM | Biogens Biosimilars Witnessed High Growth in 2Q17 Market Realist |
| 07:40AM | Biogens Spinraza Saw High Growth in 2Q17 Market Realist |
| Jul-27-17 06:05PM | How Did Biogens Multiple Sclerosis Drugs Perform in 2Q17? Market Realist |
| 04:35PM | Biogens Interferons Witnessed Steady Growth in 2Q17 Market Realist |
| 03:00PM | How Did Biogen Perform in 2Q17? Market Realist |
| 02:41PM | Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies PR Newswire |
| 12:06PM | Biogen, Inc. :BIIB-US: Earnings Analysis: Q2, 2017 By the Numbers : July 27, 2017 Capital Cube |
| 08:00AM | Today's Research Reports on Trending Tickers: Biogen Inc. and Pluristem Therapeutics Inc. ACCESSWIRE |
| 07:10AM | Corporate News Blog - Alpine Immune Sciences Goes Public on NASDAQ; Announces the Completion of an Immuno-Oncology Merger with Nivalis Therapeutics ACCESSWIRE |
| Jul-26-17 04:21PM | Biogen Inc Wants to Be the "Fastest-Growing Large-Cap Biotech Company" Motley Fool |
| 01:48PM | Lets Hear It for Biogen Inc (BIIB) Drug Spinrazas Blockbuster Potential, Raves Cowen Top Analyst SmarterAnalyst |
| 01:33PM | The biotech Goldman Sachs loves CNBC Videos |
| 11:00AM | Biogen: Now That's More Like It! Barrons.com |
| 10:09AM | 19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug Benzinga |
| 08:15AM | Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug Zacks |
| 08:15AM | Biogen shares surge 2% after upgrade to buy at Goldman Sachs MarketWatch |
| Jul-25-17 10:10PM | Biogen to streamline operations and invest more in R&D American City Business Journals |
| 09:48PM | Biogen tops Street 2Q forecasts Associated Press |
| 08:00PM | Alphabet Did Nothing to Push S&P 500 and Nasdaq to Fresh Records TheStreet.com |
| 07:57PM | Edited Transcript of BIIB earnings conference call or presentation 25-Jul-17 12:00pm GMT Thomson Reuters StreetEvents |
| 05:08PM | Biogen Says It's Under Investigation by Milan Prosecutor Bloomberg |
| 04:49PM | This Biotech Nearly Tripled Street Expectations For One Key Drug Investor's Business Daily |
| 04:06PM | [$$] Biogen's Short-Term Pain To Yield Long-Term Gain Barrons.com |
| 02:37PM | Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up Zacks |
| 02:30PM | Biogen: Where'd My Gains Go? Barrons.com |
| 12:55PM | Eli Lilly beats on earnings as stock dips CNBC Videos |
| 12:35PM | Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite TheStreet.com |
| 12:24PM | After strong quarter, Biogen rolls out growth strategy Reuters |
| 10:50AM | S&P 500 Hits All-Time High, Alphabet's Fall Pressures Nasdaq TheStreet.com |
| 09:43AM | Dow Climbs As These Blue Chips Beat; Alphabet Drags On Nasdaq Investor's Business Daily |
| 08:55AM | US STOCKS-Caterpillar, McDonald's to lift S&P, Dow at open Reuters |
| 08:17AM | Biogen (BIIB) Tops Q2 Earnings and Revenue Zacks |
|
|
|
|
| Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The company's Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkin's lymphoma; and Aducanumab and E2609 for Alzheimer's disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The company's Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| ALEXANDER SUSAN H | EVP Chief Legal Corp Svc & Sec | Jul 25 | Sale | 290.01 | 4,974 | 1,442,510 | 22,258 | Jul 26 04:22 PM | | ALEXANDER SUSAN H | EVP Chief Legal Corp Svc & Sec | Jul 19 | Sale | 285.00 | 7,758 | 2,211,030 | 27,232 | Jul 20 05:00 PM | | Posner Brian S | Director | Jun 09 | Sale | 256.31 | 1,084 | 277,840 | 6,330 | Jun 12 04:29 PM | | Ehlers Michael D | EVP, Research and Development | Jun 01 | Option Exercise | 0.00 | 1,259 | 0 | 4,027 | Jun 05 04:38 PM | | Vounatsos Michel | Chief Executive Officer | May 02 | Option Exercise | 0.00 | 1,736 | 0 | 4,663 | May 04 04:16 PM | | Vounatsos Michel | Chief Executive Officer | May 01 | Buy | 271.35 | 1,402 | 380,433 | 2,927 | May 02 04:18 PM | | DENNER ALEXANDER J | Director | Apr 27 | Buy | 278.50 | 73,858 | 20,569,476 | 383,858 | May 01 05:47 PM | | Clancy Paul J | Executive VP and CFO | Apr 25 | Sale | 290.00 | 9,892 | 2,868,680 | 10,813 | Apr 27 04:23 PM | | Sandrock Alfred | EVP CMO Neuro & Neurodegenerat | Apr 03 | Sale | 274.08 | 1,981 | 542,952 | 7,060 | Apr 04 04:18 PM | | Clancy Paul J | Executive VP and CFO | Mar 13 | Sale | 291.55 | 9,891 | 2,883,721 | 20,705 | Mar 14 07:32 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Mar 01 | Option Exercise | 0.00 | 481 | 0 | 718 | Mar 03 06:07 PM | | Sandrock Alfred | EVP CMO Neuro & Neurodegenerat | Mar 01 | Sale | 290.07 | 973 | 282,238 | 9,041 | Mar 03 06:02 PM | | Clancy Paul J | Executive VP and CFO | Feb 28 | Option Exercise | 0.00 | 6,780 | 0 | 31,948 | Mar 02 05:24 PM | | Sandrock Alfred | EVP CMO Neuro & Neurodegenerat | Feb 28 | Option Exercise | 0.00 | 4,785 | 0 | 10,398 | Mar 02 05:22 PM | | ALEXANDER SUSAN H | EVP, Chief Legal Officer | Feb 28 | Option Exercise | 0.00 | 5,559 | 0 | 36,024 | Mar 02 05:20 PM | | COVINO GREGORY F | VP, Chief Accounting Officer | Feb 28 | Option Exercise | 0.00 | 681 | 0 | 4,508 | Mar 02 05:18 PM | | Karaboutis Adriana | EVP, Tech, Bus. Sol & Corp Aff | Feb 28 | Option Exercise | 0.00 | 2,064 | 0 | 9,237 | Mar 02 05:16 PM | | DiPietro Kenneth | EVP Human Resources | Feb 28 | Option Exercise | 0.00 | 5,696 | 0 | 8,260 | Mar 02 05:12 PM | | Vounatsos Michel | Chief Executive Officer | Feb 27 | Buy | 285.39 | 1,333 | 380,425 | 1,434 | Mar 01 04:18 PM | | PANGIA ROBERT W | Director | Jan 09 | Option Exercise | 52.22 | 5,450 | 284,599 | 22,078 | Jan 10 04:15 PM | | PANGIA ROBERT W | Director | Jan 09 | Sale | 295.39 | 5,450 | 1,609,876 | 16,628 | Jan 10 04:15 PM | | Karaboutis Adriana | EVP, Tech, Bus. Sol & Corp Aff | Dec 01 | Sale | 296.53 | 48 | 14,233 | 7,360 | Dec 05 04:34 PM | | Karaboutis Adriana | EVP, Tech, Bus. Sol & Corp Aff | Oct 04 | Sale | 311.94 | 262 | 81,728 | 7,579 | Oct 05 04:24 PM | | Karaboutis Adriana | EVP, Tech, Bus. Sol & Corp Aff | Oct 03 | Sale | 313.00 | 380 | 118,940 | 7,841 | Oct 04 05:02 PM | | Karaboutis Adriana | EVP, Tech, Bus. Sol & Corp Aff | Oct 01 | Option Exercise | 0.00 | 1,982 | 0 | 9,154 | Oct 04 05:02 PM | | DORSA CAROLINE | Director | Sep 22 | Option Exercise | 53.64 | 27,570 | 1,478,855 | 44,663 | Sep 26 04:24 PM | | DORSA CAROLINE | Director | Sep 22 | Sale | 314.00 | 27,570 | 8,656,980 | 17,093 | Sep 26 04:24 PM |
|
|
|
|
|
|
